5 completed, 2 recruiting, 1 active not recruiting. 4 Phase 1, 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 3, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow MBX Biosciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism Canvuparatide, Placebo - Hypoparathyroidism | Phase 3 | Recruiting | MBX Biosciences | 160 | 2026-08-26 | 2026-10-23 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity MBX 4291, Placebo - Obesity | Phase 1 | Recruiting | MBX Biosciences | 124 | 2025-09-03 | 2026-06-09 |
| Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI) MBX 1416 (INN imapextide) - Postbariatric Hypoglycemia | Phase 2 | Completed | MBX Biosciences | 20 | 2025-08-26 | 2026-07-02 |
| Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism 400 µg of MBX 2109 once-weekly by subcutaneous injection, 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection - Hypoparathyroidism | Phase 2 | Active not recruiting | MBX Biosciences | 60 | 2024-10-31 | 2026-10-07 |
| Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism MBX 2109, Placebo - Hypoparathyroidism | Phase 2 | Completed | MBX Biosciences | 64 | 2024-08-08 | 2026-03-20 |
| Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function MBX 2109 - Renal Impairment | Phase 1 | Completed | MBX Biosciences | 25 | 2024-06-13 | 2025-10-28 |
| Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects MBX 1416 (Part A), MBX 1416 (Part B), Placebo - Postbariatric Hypoglycemia | Phase 1 | Completed | MBX Biosciences | 69 | 2023-09-18 | 2024-12-12 |
| Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects MBX 2109 (Part A), MBX 2109 (Part B), Placebo - Healthy | Phase 1 | Completed | MBX Biosciences | 76 | 2021-11-10 | 2023-08-09 |
Hypoparathyroidism (3) · Thyroid Diseases (2) · Body Weight (1) · Nutrition Disorders (1) · Obesity (1) · Overweight (1) · Renal Insufficiency (1)
United States (8) · Argentina (2) · Turkey (Türkiye) (2) · Canada (1)